Apyx Medical Corporation — Cyborg Score 5/10

Mixed
Medical Devices - Electrosurgical and Advanced Energy Technology

Strategic Profile

Apyx's Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. The company operates in two segments: Advanced Energy and Original Equipment Manufacturing (OEM), with the Advanced Energy segment deriving the majority of its revenue.

Cyborg Score Rationale

The company generated $47.9M in trailing twelve-month revenue with negative EPS of -$0.36, reflecting profitability challenges. While Renuvion and J-Plasma effectiveness is supported by more than 90 clinical documents, the small market capitalization and modest revenue base present growth constraints.

Top Insights

  • AYON Body Contouring System is an FDA-cleared platform that combines fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction
  • Current market capitalization is $164M with 41M shares outstanding as of late November 2025
  • Apyx, formerly Bovie® Medical, leverages deep expertise and decades of experience in unique waveforms
  • The company leverages its expertise through OEM agreements with other medical device manufacturers

Named Competitors

  • Electrosurgical Systems — Surgical instruments and electrosurgical equipment
  • Orthopedic Devices — Orthopedic surgical solutions
  • Surgical Equipment — Minimally invasive surgical devices

Recent Developments

  • (September 2025) Introduction of AYON Body Contouring System and micro handpiece expansion
  • (2025) Physician engagement initiatives at major medical conferences
  • (2024-2025) Product portfolio expansion including new micro handpiece technology

Open the full interactive Apyx Medical Corporation report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →